News section

Monsanto Company reports second-quarter 2005 results
St. Louis, Missouri
April 6, 2005
 

Financial Summary

($ in millions, except per share)

Second Quarter 2005

Second Quarter 2004

%

Change

Six Months 2005

Six Months 2004

% Change

Net Sales

$1,909

$1,498

27%

$2,985

$2,521

18%

Net Income

 

$373

$154

142%

$333

$57

484%

Diluted Earnings per Share

$1.37

$0.57

140%

$1.23

$0.21

486%

 

·     Second-quarter sales increased 27 percent, primarily because of higher corn and soybean trait revenues in the United States, increased corn seed sales in the United States and the Europe-Africa region, and higher revenues for Roundup and other glyphosate-based herbicides in all major world areas.  Similarly, sales for the first half of fiscal year 2005 increased 18 percent, benefiting from strong trait revenues, seed sales, and overall Roundup and other glyphosate-based herbicide revenues.

·     Reported net income for the quarter was $373 million, which includes after-tax restructuring charges of $6 million and income on discontinued operations of $2 million associated with the planned sale of the environmental technologies businesses.  For the first half of 2005, reported net income was $333 million, including a pre-tax charge of $284 million ($181 million aftertax) to establish a reserve associated with the Solutia Inc. bankruptcy proceedings, a tax benefit of $106 million ($86 million in discontinued operations and $20 million in continuing operations) as a result of the loss incurred on the European wheat and barley business, $7 million in after-tax restructuring charges, and income on discontinued operations of $2 million.

Comment from Monsanto Chairman, President and Chief Executive Officer Hugh Grant: 

“The second quarter is the most important single quarter in our fiscal year.  We believe the strong results this quarter, and so far this year, emphasize both the value of our leadership position in the seeds and traits market, and the continued opportunity we see as the momentum in our seeds and traits business helps propel our overall business growth.”

Second-Quarter and First-Half 2005 Performance Summary:

Net sales increased 27 percent to $1.9 billion in the second quarter primarily because of higher corn and soybean trait revenues in the United States, increased corn seed sales in the United States and the Europe-Africa region, and higher revenues for Roundup and other glyphosate-based herbicides in all major world areas.  For the quarter, sales in the Seeds and Genomics segment increased by 35 percent on the strength of increased seed and trait sales.  There was also a 17 percent improvement in sales in the Agricultural Productivity segment, as sales of branded Roundup herbicides and other glyphosate-based herbicides increased. 

For the first half of 2005, net sales approached $3 billion, an 18 percent improvement compared with net sales in the same period last year.  The drivers for the first-half sales included increases in U.S. corn and soybean trait revenues, and increased corn seed sales in the United States and the Europe-Africa region.  Additionally, sales of Roundup and other glyphosate-based herbicides outside the United States were higher for the first half of 2005, particularly in Brazil and Europe. 

Net income and earnings per share:  Monsanto recorded second-quarter fiscal year 2005 net income of $373 million, or $1.37 per share, compared with net income of $154 million, or $0.57 per share, in the second quarter of fiscal year 2004. 

Items affecting comparability for second quarter of 2005 included:

  • Net restructuring charges of $(0.02) per share.

  • $0.01 per share income on discontinued operations.

Items affecting comparability for second quarter of 2004 included:

  • Net restructuring charges of $(0.12) per share.

  • A $(0.01) per share loss on discontinued operations and related restructuring.

The company’s first-half fiscal year 2005 net income was $333 million, or $1.23 per share, compared with net income of $57 million, or $0.21 per share, for the same period in 2004. 

Items affecting comparability for the first half of fiscal year 2005 included:

  • A $(0.67) per share charge associated with certain liabilities in connection with the Solutia bankruptcy (“Solutia-related charge”).

  • A $0.39 per share tax benefit ($0.32 in discontinued operations and $0.07 in continuing operations) as a result of the loss incurred on the European wheat and barley business.

  • Net restructuring charges of $(0.03) per share.

  • $0.01 per share income on discontinued operations.

 Items affecting comparability for the first half of fiscal year 2004 included:

  • Net restructuring charges of $(0.19) per share.

  • A $(0.08) per share loss on discontinued operations and related restructuring.

  • Write-off of goodwill associated with the global wheat business of $(0.26) per share.

Operating costs:  Research-and-development (R&D) expenses were slightly higher at $127 million for the second quarter.  For the first half of fiscal year 2005, R&D expenses were 7 percent higher at $258 million, driven by the write-off of in-process R&D costs associated with the acquisition of the North American canola seed businesses of Advanta Seeds, as well as the acquisition of Channel Bio Corp. by Monsanto’s American Seeds, Inc. subsidiary. 

Selling, general and administrative (SG&A) expenses for second quarter 2005 were $303 million, compared to $272 million in the second quarter of 2004.  For the first half of fiscal year 2005, SG&A expenses were $559 million, compared to $544 million in the same period in 2004.  However, for the quarter and the first half, SG&A as a percent of net sales decreased versus the comparable prior periods.  For the second quarter of fiscal year 2005, SG&A as a percent of sales was 16 percent.  For the first half, SG&A as a percent of sales was 19 percent. 

Cash flow:  Year-to-date 2005 net cash provided by operations was $453 million, compared with $217 million through the first half of fiscal year 2004.  Net cash provided (required) by investing activities was $47 million through the first half of the fiscal year 2005, and $(146) million for the same period in 2004.  As a result, year-to-date free cash flow increased from $71 million in the first half of 2004 to $500 million in this year’s first half.  Free cash flow in the first half of fiscal year 2004 was affected by payments of $400 million related to the Solutia PCB litigation settlement.  Additionally, the increase in free cash flow for the first half of fiscal year 2005 resulted from the timing of maturities of short-term investments, which was somewhat offset by Monsanto’s seed acquisitions. (For a reconciliation of free cash flow, see note 1.

Seeds and Genomics Segment Detail

Net Sales

($ in millions)

Second Quarter 2005

Second Quarter 2004

 

% Change

Six Months   2005

Six

Months   2004

 

%
Change

Corn seed and traits

$646

$488

32%

$874

$677

29%

Soybean seed and traits

$443

$316

40%

$623

$489

27%

All other crops seeds and traits

$92

$70

31%

$153

$101

51%

TOTAL Seeds and Genomics

$1,181

$874

35%

$1,650

$1,267

30%

The Seeds and Genomics segment consists of the global seeds and related trait business, and genetic technology platforms. 

Second-quarter 2005 net sales of $1,181 million for the Seeds and Genomics segment were more than one-third higher than sales of $874 million recorded in the second quarter of fiscal year 2004.  This improvement was largely driven by increased revenues in both corn seed and traits and soybean seed and traits.  Corn seed and traits increased 32 percent in the quarter-over-quarter comparison, reflecting higher corn seed and trait sales in the United States and corn seed sales in Europe.  Soybean seed and traits net sales increased 40 percent, primarily driven by higher revenues for soybean traits in the United States. 

For the first half of fiscal year 2005, the Seeds and Genomics segment recorded an increase in sales of 30 percent to approximately $1.7 billion, driven by the increased revenues in the corn seeds and traits and soybean seeds and traits businesses.

EBIT (net income (loss) before interest and taxes) for the Seeds and Genomics segment increased 240 percent, or $358 million, in the first half of fiscal year 2005, compared with the first half of 2004.  The improvement in EBIT for the first half of 2005 was driven primarily by increased revenue for traits, which reflects increased penetration, pricing flexibility and the value of stacking more than one trait in a single seed. (For a reconciliation of EBIT, see note 1.)

Agricultural Productivity Segment Detail

Net Sales

($ in millions)

Second Quarter 2005

Second Quarter 2004

 

% Change

Six

Months

 2005

Six

Months

 2004

 

%
Change

Roundup and other glyphosate-based agricultural herbicides

$481

$371

30%

$919

$807

14%

All other agricultural  productivity products

$247

$253

(2)%

$416

$447

(7)%

TOTAL Agricultural Productivity

$728

$624

17%

$1,335

$1,254

6%

The Agricultural Productivity segment consists primarily of crop protection products, the lawn-and-garden herbicide products, and the company’s animal agricultural businesses. 

Net sales in the Agricultural Productivity segment for the quarter improved by 17 percent, driven by increased net sales of Roundup and other glyphosate-based herbicides in all major world areas.  For the quarter, overall sales of Roundup and other glyphosate-based herbicides increased, with increased sales of branded Roundup herbicide in all major world areas outside of the United States.  Additionally, sales of non-branded glyphosate-based herbicides also contributed to the quarterly sales increase.  The increase in sales for Roundup and other glyphosate-based herbicides was offset by a slight decline in revenues from all other agricultural products, which decreased 2 percent in second quarter fiscal year 2005.

Compared with the first half of fiscal year 2004, the Agricultural Productivity segment recorded a slight increase in sales of 6 percent in the first half of fiscal year 2005, driven by increased revenues for Roundup and other glyphosate-based herbicides.  Sales of branded Roundup herbicide were down modestly for the first half of the fiscal year as higher sales outside the United States were offset by decreased U.S. sales due to lower pricing.  For the first half of fiscal year 2005, higher non-branded glyphosate sales also contributed to the overall increase in sales. 

EBIT for the Agricultural Productivity segment decreased $189 million in the first half of fiscal year 2005, compared with the first half of 2004.  The decrease in EBIT for the first half of 2005 was driven primarily by the Solutia-related charge, which was somewhat offset by lower operating expenses and improved sales of Roundup and other glyphosate-based herbicides. (For a reconciliation of EBIT, see note 1.)

Outlook Comment from Monsanto Chairman, President and Chief Executive Officer Hugh Grant:

“Following the acquisitions of Seminis and Emergent, our focus is on the task of execution and acceleration as we look to build on the positive momentum in our seeds and traits business.  We continue to remain focused and disciplined, but we’re also more comfortable that our performance to date will allow us to reach the growth targets we’ve established for this year and successive years.”

2005 Earnings and Free Cash Flow Outlook:

On March 29, Monsanto provided updated EPS guidance for fiscal year 2005, with EPS on an ongoing business basis expected to be in the range of $2.00 to $2.05.  The ongoing EPS guidance excludes estimated in-process R&D and other purchase accounting adjustments of $0.78 to $0.85 per share, the $0.67 per-share Solutia-related charge, the tax benefit of $0.39 per share as a result of the loss incurred on the European wheat and barley business, a $0.03 per-share charge for restructuring, and $0.01 per share income on discontinued operations.  On an as-reported basis, Monsanto expects EPS to be in the range of
$0.85 to $0.97.  (For a reconciliation of ongoing EPS, see note 1.)  Previously, Monsanto provided updated EPS guidance for fiscal year 2005, with EPS on an ongoing business basis expected to be toward the upper end of the $1.85 to $2.00 range, or in the range of $0.71 to $0.93 on an as-reported basis. 

Monsanto expects cash from operations to be $1.2 billion. Including free cash to be used for the Seminis and Emergent purchases, the company expects net cash required by investing activities to be $2.1 billion. As a result, the company expects free cash flow to be negative $900 million for the fiscal year.  (For a reconciliation of free cash flow, see note 1.)

Other Items of Note:

On April 5, Monsanto announced completed the acquisition of Emergent Genetics’ cotton business.  Emergent will be integrated into Monsanto’s existing commercial operations. 

On April 5, Monsanto announced that it signed a non-binding letter of intent to sell its Enviro-Chem unit to the management of this subsidiary in a management buyout.  The parties are currently working on a definitive agreement for the transaction, which is targeted to close by the end of Monsanto’s 2005 fiscal year.

On March 24, Brazil’s President Luiz Inacio Lula da Silva signed a biosafety bill into law which establishes the regulatory process for the approval of biotech crops.  This law demonstrates that Brazil supports a science-based regulatory system and is another indication of the growing acceptance of biotechnology around the world.

On March 24, Monsanto announced it had acquired selected agricultural assets of Icoria Inc. for $6.75 million in cash, installment and milestone payments, plus additional considerations.  Monsanto acquired assets related to functional genomics and transgenic applications, which will be used in Monsanto’s discovery program.

On March 23, Monsanto and the University of Nebraska-Lincoln signed an exclusive licensing agreement to develop crops tolerant to the broadleaf herbicide dicamba. 

On March 18, Brazil's regulatory body, the National Commission for Biosafety, approved Monsanto’s Bollgard insect-protected cotton. 

On March 15, Monsanto announced it obtained U.S. regulatory clearance for its next-generation cotton technology, Roundup Ready Flex cotton. The U.S. regulatory clearance represents an important step forward toward the anticipated commercial launch for the 2006 growing season. Regulatory clearances in other key production and export countries are anticipated later this fiscal year.

On March 14, Monsanto announced a new collaborative relationship with Modular Genetics Inc. (MGI) to advance Monsanto's protein optimization platform.  Monsanto gains an exclusive license to MGI's platform for use in agricultural applications. Applying this platform, Monsanto will be able to accelerate its ability to identify and develop new traits for platforms like agronomic traits, enhanced nutritional content and improved yield properties.

On March 1, Monsanto’s American Seeds, Inc. subsidiary announced it added NC+ Hybrids, Inc. to its family of regional brands established to help serve farmer-customers with a technology-rich, locally-oriented business model.

Supplemental data to this news release, including slides that accompany the company’s financial results conference call, are found at www.monsanto.com.  To access this supplemental information, please go to the Investor Information section of the web site.

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality.

Roundup, Bollgard and Roundup Ready are registered trademarks owned by Monsanto Company and its wholly owned subsidiaries.

Unless otherwise indicated, references to “Roundup and other glyphosate-based herbicides” mean both branded and non-branded glyphosate-based herbicides, excluding all lawn-and-garden herbicide products.
 

Monsanto Company and Subsidiaries

Selected Financial Information

(Dollars in millions, except per share amounts)

Unaudited

 

Condensed Statement of Consolidated Operations

Three Months

Ended

Feb. 28, 2005

Three Months

Ended

Feb. 29, 2004

Six Months

Ended

Feb. 28, 2005

Six Months

Ended

Feb. 29, 2004

Net Sales

$1,909

$1,498

$2,985

$2,521

Cost of Goods Sold

893

755

1,474

1,317

Gross Profit

1,016

743

1,511

1,204

Operating Expenses:

 

 

 

 

     Selling, General and Administrative Expenses

303

272

559

544

     Bad-Debt Expense

11

22

21

40

      Research and Development Expenses

127

125

258

241

      Impairment of Goodwill

69

      Restructuring Charges – Net

7

28

8

57

Total Operating Expenses

448

447

846

951

Income From Operations

568

296

665

253

Interest Expense – Net

15

15

35

32

Solutia-Related Expenses

9

14

293

14

Other Expense – Net

19

23

42

48

Income From Continuing Operations Before Income Taxes

525

244

295

159

Income Tax Provision

154

88

50

82

Income From Continuing Operations

371

156

245

77

Discontinued Operations:

 

 

 

 

      Income (Loss) From Operations of Discontinued Businesses

 

2

 

(3)

 

2

 

(28)

      Income Tax Benefit

(1)

(86)

(8)

Income (Loss) on Discontinued Operations

2

(2)

88

(20)

Net Income

$  373

$   154

$   333

$     57

EBIT (1)

 

$  542

 

$   256

 

$   332

 

$   163

Basic Earnings (Loss) Per Share:

 

 

 

 

Income From Continuing Operations

$ 1.39

$ 0.59

$  0.92

$   0.29

Income (Loss) on Discontinued Operations

0.01

(0.01)

0.33

(0.07)

Net Income

$ 1.40

$ 0.58

$  1.25

$   0.22

 

 

 

 

 

Diluted Earnings (Loss) Per Share:

 

 

 

 

Income From Continuing Operations

$ 1.36

$ 0.58

$  0.90

$   0.29

Income (Loss) on Discontinued Operations

0.01

(0.01)

                0.33

(0.08)

Net Income

$ 1.37

$ 0.57

$  1.23

$   0.21

 

 

 

 

 

Weighted Average Shares Outstanding:

 

 

 

 

     Basic Shares

266.5

264.3

265.6

263.2

     Diluted Shares

272.9

268.8

271.3

267.4

 

Monsanto Company and Subsidiaries

Selected Financial Information
(Dollars in millions)
Unaudited

Condensed Statement of Consolidated Financial Position

As of
Feb. 28, 2005

As of
Aug. 31, 2004

Assets

 
 

 

 

 

Current Assets:

 

 

    Cash and Cash Equivalents

$1,096

 $1,037

Short-Term Investments

300

    Trade Receivables – Net of Allowances of $259 and $250, respectively

 

1,913

 

1,663

    Miscellaneous Receivables         

368

316

    Deferred Tax Assets

366

397

    Inventories

1,379

1,154

    Assets of Discontinued Operations

67

    Other Current Assets

87

64

Total Current Assets

5,276

4,931

 

 

 

Property, Plant and Equipment – Net

2,057

2,087

Goodwill – Net

869

720

Other Intangible Assets – Net

446

454

Other Assets

1,195

972

Total Assets

$9,843

$9,164

 

 

 

Liabilities and Shareowners’ Equity

 

 

 

 

 

Current Liabilities:

 

 

    Short-Term Debt

$     99

$  433

    Accounts Payable

360

326

Income Taxes Payable

172

122

Accrued Marketing Programs

264

419

Deferred Revenues

237

16

    Grower Accruals

48

1

    Liabilities of Discontinued Operations      

37

    Miscellaneous Short-Term Accruals

593

577

Total Current Liabilities

1,810

1,894

 

 

 

Long-Term Debt

1,062

1,075

Postretirement Liabilities

665

687

Solutia-Related Reserve

202

Other Liabilities

274

250

Shareowners’ Equity

5,830

5,258

Total Liabilities and Shareowners’ Equity

$9,843

$9,164

 

 

 

Debt to Capital Ratio:

17%

22%

 

Monsanto Company and Subsidiaries

Selected Financial Information
(Dollars in millions)
Unaudited
 

Statement of Consolidated Cash Flows

Six Months Ended

Feb. 28, 2005

Six Months Ended

Feb. 29, 2004

 

Operating Activities:

 

 

    Net Income

$  333

$ 57

    Adjustments to reconcile cash provided (required) by operations:

 

 

    Items that did not require (provide) cash:

 

 

        Depreciation and amortization expense

221

228

        Impairment of goodwill

69

        Impairment of assets included in discontinued operations

29

        Bad-debt expense

21

40

        Noncash restructuring

7

32

        Deferred income taxes

(143)

246

        Gain on disposal of investments and property – net

(5)

(5)

        Equity affiliate expense – net

15

20

        Solutia-related charge

284

        Other items that did not require cash

38

19

Changes in assets and liabilities that provided (required) cash, net of acquisitions:

 

 

        Trade receivables

65

478

        Inventories

(157)

(79)

        Accounts payable and accrued liabilities

(163)

(400)

        PCB litigation settlement insurance proceeds (payments)

4

(400)

        Solutia-related reserve

(29)

        Pension contributions

(60)

(150)

        Other Items

22

33

Net Cash Provided by Operations

453

217

 

 

 

Cash Flows Provided (Required) by Investing Activities:

 

 

Purchases of short-term investments

(250)

Maturities of short-term investments

300

230

Acquisitions of businesses, net of cash acquired

(173)

Technology and other investments

(20)

(33)

Capital expenditures

(83)

(103)

Other investment and property disposal proceeds

23

10

Net Cash Provided (Required) by Investing Activities

47

(146)

 

 

 

Cash Flows Provided (Required) by Financing Activities:

 

 

Net change in financing with less than 90-day maturities

(95)

(49)

Short-term debt proceeds

5

5

Short-term debt reductions

(15)

(10)

Long-term debt proceeds

11

101

Long-term debt reductions

(278)

(43)

Payments on other financing

(3)

(3)

Treasury stock purchases

(74)

(106)

Stock option exercises

92

119

Dividend payments

(84)

(68)

Net Cash Required by Financing Activities

 (441)

(54)

 

 

 

Net Increase in Cash and Cash Equivalents

59

17

Cash and Cash Equivalents at Beginning of Period

1,037

281

Cash and Cash Equivalents at End of Period

$1,096

                $298


 

Monsanto Company and Subsidiaries

Selected Financial Information
(Dollars in millions)
Unaudited 

1.   EBIT, Ongoing EPS, and Free Cash Flow:  The presentations of EBIT, ongoing EPS and free cash flow are not intended to replace net income (loss), cash flows, financial position or comprehensive income (loss), and they are not measures of financial performance as determined in accordance with generally accepted accounting principles (GAAP) in the United States.  The following tables reconcile EBIT, ongoing EPS and free cash flow to the respective most directly comparable financial measure calculated in accordance with GAAP.

Reconciliation of EBIT to Net Income:  EBIT is defined as net income (loss) before interest and  taxes. The following table reconciles EBIT to the most directly comparable financial measure, which is net income. 

 

Total Monsanto Company and Subsidiaries:

Three Months

Ended

Feb. 28, 2005

Three Months

Ended

Feb. 29, 2004

Six Months

Ended

Feb. 28, 2005

Six Months

Ended

Feb. 29, 2004

 

 

 

 

 

EBIT – Seeds and Genomics Segment

$492

$273

$507

 $149

EBIT – Agricultural Productivity Segment

50

(17)

(175)

14

EBIT – Total Monsanto Company and      Subsidiaries

 

542

 

256

 

332

 

163

Interest Expense – Net

15

15

35

32

Income Tax Provision (Benefit)(1)

154

87

(36)

74

Net Income

$373 

$154

$333 

$ 57

          (1)  Includes the income tax provision from continuing operations and the income tax benefit from discontinued operations.

Reconciliation of EPS to Ongoing EPS: Ongoing EPS is calculated excluding certain after-tax items which Monsanto does not consider part of ongoing operations. 

 

 

Total Monsanto Company and Subsidiaries:

 

Fiscal Year

2005

Target

Three Months

Ended

Feb. 28, 2005

Three Months

Ended

Feb. 29, 2004

Six

Months Ended

Feb. 28, 2005

Six

Months Ended

Feb. 29, 2004

 

 

 

 

 

 

Diluted Earnings per Share

$0.85 – $0.97

$1.37

$0.57

$1.23

$0.21

Estimated In-Process R&D and Other
    Purchase Accounting Adjustments

0.78 0.85

 

 

 

 

Solutia-Related Charge

0.67

0.67

Tax Benefit on Loss from European Wheat and        Barley  Business

(0.39)

(0.39)

Restructuring Charges – Net

0.03

0.02

0.12

0.03

0.19

(Income) Loss on Discontinued Operations and

    Related Restructuring   

(0.01)

(0.01)

0.01

(0.01)

0.08

Impairment of Goodwill

0.26

Diluted Earnings per Share from Ongoing     Operations

 

$2.00 – $2.05

 

$1.38

 

$0.70

 

$1.53

 

$0.74

 

Reconciliation of Free Cash Flow: Free cash flow represents the total of cash flows from operations and investing activities, as reflected in Monsanto’s Statement of Consolidated Cash Flows presented in this release.  With respect to the projected free cash flow guidance provided under the caption “2005 Earnings and Free Cash Flow Outlook,” Monsanto does not include any estimates or projections of Net Cash Provided (Required) by Financing Activities because in order to prepare any such estimate or projection, Monsanto would need to rely on market factors and conditions that are outside of its control.

 

 

Total Monsanto Company and Subsidiaries:

Fiscal Year

2005

Target

Six Months Ended

Feb. 28, 2005

Six Months Ended

Feb. 29, 2004

 

 

 

 

Net Cash Provided by Operations

$1,200

$   453

$ 217

Net Cash Provided (Required) by Investing Activities

  (2,100)

      47

(146)

Free Cash Flow

$ (900)

$   500

$  71

Net Cash Required by Financing Activities

  N/A

(441)

(54)

Net Increase in Cash and Cash Equivalents

  N/A

$     59

$  17

Cash and Cash Equivalents at Beginning of Period

 N/A

  1,037

  281

Cash and Cash Equivalents at End of Period

 N/A

$1,096

$298

  

1.      
Restructuring:  In October 2003, Monsanto announced plans to continue to reduce the costs associated with its agricultural chemistry business as that segment matures globally. These plans included: (1) reducing costs associated with the company’s Roundup herbicide business; (2) exiting the European breeding and seed business for wheat and barley; and (3) discontinuing the plant-made pharmaceuticals program. In fiscal year 2004, total charges related to these actions were $105 million aftertax. Additionally, the plans included the impairment of goodwill in the global wheat business of $69 million. In fiscal year 2005, the company incurred charges of $8 million pretax ($7 million aftertax) to complete the restructuring actions under this plan. No further actions are planned in 2005.

Activities related to the restructuring plan items were recorded in the Condensed Statement of Consolidated Operations in the following categories: 

 

Total Monsanto Company and Subsidiaries:

Three Months

Ended

Feb. 28, 2005

Three Months

Ended

Feb. 29, 2004

Six Months

Ended

Feb. 28, 2005

Six Months

Ended

Feb. 29, 2004

    Cost of Goods Sold

          $ —

        $ (17)

          $ —

        $ (17)

    Impairment of Goodwill

             —

             —

             —

           (69)

    Restructuring Charges – Net(1,2)

              (7)

           (28)

              (8)

           (57)

Loss From Continuing Operations Before Income Taxes

              (7)

           (45)

              (8)

         (143)

      Income Tax Benefit

               1

             13

             21

             24

Income (Loss) From Continuing Operations

              (6)

           (32)

             13

         (119)

Loss From Operations of Discontinued Businesses

             —

              (1)

             —

           (34)

    Income Tax Benefit

             —

               1

             —

             10

Loss On Discontinued Operations

             —

             —

             —

           (24)

Net Income (Loss)

          $ (6)

        $ (32)

         $ 13

        $ (95)

 

(1)  The $8 million of restructuring charges for the six months ended Feb. 28, 2005, was split by segment as follows: $7 million in the Seeds and Genomics segment (recorded in the three months ended Feb. 28, 2005) and $1 million in the Agricultural Productivity segment.

(2)  The restructuring charges for the three months and six months ended Feb. 29, 2004, were offset by prior-plan restructuring reversals of $1 million and $2 million, respectively.

In first quarter 2005, Monsanto recorded a deferred tax benefit of $106 million, of which $20 million was recorded in continuing operations, and the remaining $86 million was recorded in discontinued operations. The $20 million tax benefit recorded in continuing operations is related to the impairment of goodwill in the global wheat business as part of the fiscal year 2004 restructuring plan and thus is included in the table above.  The tax benefit of $86 million recorded in discontinued operations was primarily related to the goodwill impairment loss at the date of adoption of SFAS 142, Goodwill and Other Intangible Assets (SFAS 142), on Jan. 1, 2002, and thus is not reflected in the table above. Upon adoption of SFAS 142, the goodwill impairment was recorded as a cumulative effect of a change in accounting principle, and the impairment for the wheat reporting unit was primarily related to the discontinued European wheat and barley business.

Depreciation and Amortization:  The following table displays the depreciation and amortization expense by segment for the three months and six months ended Feb. 28, 2005, and Feb. 29, 2004:
 

 

Depreciation and Amortization Expense

Three Months

Ended

Feb. 28, 2005

Three Months

Ended

Feb. 29, 2004

Six Months

Ended

Feb. 28, 2005

Six Months

Ended

Feb. 29, 2004

 

 

 

 

 

Seeds and Genomics(1)

$  65

$  70

$128

$135

Agricultural Productivity

   47

   44

  93

  93

Total Monsanto

$112

$114

$221

$228

 (1) Does not include the $69 million impairment of goodwill in the first half of fiscal year 2004.

 

Download the results in PDF Format: http://www.monsanto.com/monsanto/content/investor/financial/reports/2005/Q22005EarningsRelease.pdf

 

News release

Other news from this source

11,884

Back to main news page

The news release or news item on this page is copyright © 2005 by the organization where it originated.
The content of the SeedQuest website is copyright © 1992-2005 by SeedQuest - All rights reserved
Fair Use Notice